David Jellyman

US Patent:

20210024630, Jan 28, 2021

Filed:

Mar 26, 2019

Appl. No.:

17/040513

Inventors:

- Redmond WA, US
- Chengdu, Sichuan, CN
Dong XIA - Redmond WA, US
David JELLYMAN - Duvall WA, US
Katrina BYKOVA - Seattle WA, US
Anne-Marie ROUSSEAU - Seattle WA, US
Bill BRADY - Bothell WA, US
Blair RENSHAW - Renton WA, US
Brian KOVACEVICH - Snohomish WA, US
Yu LIANG - Redmond WA, US
Camilla WANG - Sammamish WA, US
Zeren GAO - Redmond WA, US
Hui Huang - Redmond WA, US

International Classification:

C07K 16/28
A61P 35/02
C12N 5/0783
C12N 5/09

Abstract:

The application provides guidance and navigation control (GNC) proteins. In one embodiment, the guidance and navigation control (GNC) protein, comprising a binding domain for a T cell activating receptor, a binding domain for a tumor associated antigen, a bind domain for an immune checkpoint receptor, and a binding domain for a T cell co-stimulating receptor. The binding domain for the tumor associated antigen is not adjacent to the binding domain for the T cell co-stimulating receptor. In one embodiment, the binding domain for the T cell activating receptor is adjacent to the binding domain for the tumor associated antigen (TAA).

US Patent:

20210008113, Jan 14, 2021

Filed:

Mar 26, 2019

Appl. No.:

17/040519

Inventors:

- Redmond WA, US
- Chengdu, Sichuan, CN
Jahan KHALILI - Everett WA, US
Dong XIA - Redmond WA, US
David JELLYMAN - Duvall WA, US
Katrina BYKOVA - Seattle WA, US
Anne-Marie ROUSSEAU - Seattle WA, US
Camilla WANG - Sammamish WA, US
Zeren GAO - Redmond WA, US
Hui HUANG - Redmond WA, US
Steven K. LUNDY - Woodinville WA, US

International Classification:

A61K 35/17
C12N 5/0783
G01N 33/574
C07K 14/725
C07K 14/705
C07K 16/28
A61P 35/00

Abstract:

The application provides methods for generating a therapeutic composition. The method includes the steps of providing a cell material comprising a cytotoxic cell, incubating the cell material with a first GNC protein to provide an activated cell composition, wherein the activated cell composition comprises a first therapeutic cell, and formulating the activated cell composition to provide a therapeutic composition, wherein the therapeutic composition is substantially free of exogenous viral and non-viral DNA or RNA. The first GNC protein comprises a first cytotoxic binding moiety and a first cancer targeting moiety, wherein the first cytotoxic binding moiety has a specificity to a first cytotoxic cell receptor and is configured to activate the first cytotoxic cell, and wherein the first cancer targeting moiety has a specificity to a first cancer cell receptor. The first therapeutic cell comprises the first GNC protein bound to the cytotoxic cell through the first cytotoxic cell receptor.

US Patent:

20200157213, May 21, 2020

Filed:

Jun 22, 2018

Appl. No.:

16/615117

Inventors:

- Redmond WA, US
- Chengdu, CN
Dong XIA - Redmond WA, US
David JELLYMAN - Duvall WA, US
Katrina BYKOVA - Seattle WA, US
Anne-Marie K. ROUSSEAU - Seattle WA, US
Bill BRADY - Bothell WA, US
Blair RENSHAW - Renton WA, US
Brian KOVACEVICH - Snohomish WA, US
Yu LIANG - Redmond WA, US
Zeren GAO - Redmond WA, US

International Classification:

C07K 16/28
A61K 47/68
A61K 39/395
A61K 45/06

Abstract:

The application provides tri-specific antibody monomers having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a Fab domain, a Fc domain, and a second scFv domain at the C-terminal. In one embodiment, the first scFv domain, the Fab domain, and the second scFv domain each has a binding specificity against a different antigen.

US Patent:

20200157217, May 21, 2020

Filed:

Jun 22, 2018

Appl. No.:

16/615109

Inventors:

- Redmond WA, US
- Chengdu, Sichuan, CN
Dong XIA - Redmond WA, US
David JELLYMAN - Duvall WA, US
Brian KOVACEVICH - Snohomish WA, US
Bill BRADY - Bothell MA, US
Blair RENSHAW - Renton WA, US
Zeren GAO - Redmond WA, US
Yi ZHU - Chengdu, CN

International Classification:

C07K 16/28
A61K 47/68
C12N 15/85

Abstract:

The applications provides the anti-CD3 monoclonal antibodies, antigen-binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to active CD3+ T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.

US Patent:

20200157224, May 21, 2020

Filed:

Jun 22, 2018

Appl. No.:

16/615123

Inventors:

- Redmond WA, US
- Chengdu, CN
Dong XIA - Redmond WA, US
David JELLYMAN - Duvall WA, US
Katrina BYKOVA - Seattle WA, US
Anne-Marie K. ROUSSEAU - Seattle WA, US
Bill BRADY - Bothell WA, US
Blair RENSHAW - Renton WA, US
Brian KOVACEVICH - Snohomish WA, US
Yu LIANG - Redmond WA, US
Zeren GAO - Redmond WA, US

International Classification:

C07K 16/28
C07K 16/32
A61K 35/16

Abstract:

The disclosure provides a tetra-specific antibody monomer having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a second scFv domain, a Fab domain, a Fc domain, and a third scFv at the C-terminal, wherein the first scFv domain, the second scFv domain, the Fab domain, and the third scFv domain each has a binding specificity against a different antigen. In one embodiment, the antigen is a tumor antigen, an immune signaling antigen, or a combination thereof. In one embodiment, the antigen includes CD19, CD3, CD137, 4-1BB, and PD-L1. Multi-specific antibodies comprising the disclosed tetra-specific antibodies are also provided.